LT3219726T - Anti-tnf alfa antikūnai ir jų funkciniai fragmentai - Google Patents

Anti-tnf alfa antikūnai ir jų funkciniai fragmentai

Info

Publication number: LT3219726T
Authority: LT; Lithuania
Prior art keywords: functional fragments; tnf alpha; alpha antibodies; antibodies; tnf
Prior art date: 2016-03-17

Application number

LTEP16160907.8T

Other languages

English (en)

Inventor

Tea Gunde

Sebastian Meyer

Esther Maria FURRER

Original Assignee

Tillotts Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-03-17

Filing date

2016-03-17

Publication date

2021-01-25

2016-03-17 Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag

2021-01-25 Publication of LT3219726T publication Critical patent/LT3219726T/lt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

LTEP16160907.8T 2016-03-17 2016-03-17 Anti-tnf alfa antikūnai ir jų funkciniai fragmentai LT3219726T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP16160907.8A EP3219726B1 (en)	2016-03-17	2016-03-17	Anti-tnf alpha-antibodies and functional fragments thereof

Publications (1)

Publication Number	Publication Date
LT3219726T true LT3219726T (lt)	2021-01-25

Family

ID=55542576

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP16160907.8T LT3219726T (lt)	2016-03-17	2016-03-17	Anti-tnf alfa antikūnai ir jų funkciniai fragmentai
LTEPPCT/EP2017/056237T LT3430043T (lt)	2016-03-17	2017-03-16	Anti-tnf alfa antikūnai ir funkciniai jų fragmentai

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/EP2017/056237T LT3430043T (lt)	2016-03-17	2017-03-16	Anti-tnf alfa antikūnai ir funkciniai jų fragmentai

Country Status (40)

Country	Link
US (3)	US11459383B2 (lt)
EP (3)	EP3219726B1 (lt)
JP (2)	JP7129398B2 (lt)
KR (2)	KR20220158877A (lt)
CN (1)	CN109071650B (lt)
AR (1)	AR107917A1 (lt)
AU (2)	AU2017235387B2 (lt)
CA (1)	CA3011784C (lt)
CL (1)	CL2018002649A1 (lt)
CO (1)	CO2018009783A2 (lt)
CR (1)	CR20180448A (lt)
CY (1)	CY1123784T1 (lt)
DK (2)	DK3219726T3 (lt)
EA (1)	EA039760B1 (lt)
ES (3)	ES2836349T3 (lt)
FI (1)	FI3430043T3 (lt)
GE (2)	GEP20217307B (lt)
HR (2)	HRP20231464T1 (lt)
HU (2)	HUE052773T2 (lt)
IL (2)	IL261031B2 (lt)
JO (2)	JOP20170064B1 (lt)
LT (2)	LT3219726T (lt)
MA (1)	MA43717B1 (lt)
MD (1)	MD3430043T2 (lt)
MX (1)	MX2018011258A (lt)
MY (1)	MY194041A (lt)
PH (1)	PH12018501907A1 (lt)
PL (2)	PL3219726T3 (lt)
PT (2)	PT3219726T (lt)
RS (2)	RS61374B1 (lt)
SA (1)	SA518400027B1 (lt)
SG (1)	SG11201807062RA (lt)
SI (2)	SI3219726T1 (lt)
SM (2)	SMT202000706T1 (lt)
TN (1)	TN2018000298A1 (lt)
TW (2)	TWI829444B (lt)
UA (1)	UA128715C2 (lt)
UY (1)	UY37157A (lt)
WO (1)	WO2017158092A1 (lt)
ZA (5)	ZA201805919B (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017158084A1 (en)	2016-03-17	2017-09-21	Numab Innovation Ag	ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
SMT202000706T1 (it) *	2016-03-17	2021-01-05	Tillotts Pharma Ag	Anticorpi anti-tnf alfa e frammenti funzionali di essi
CN108884156B (zh)	2016-03-17	2021-10-01	努玛创新有限公司	抗TNFα抗体及其功能片段
EP3219727B1 (en)	2016-03-17	2020-12-16	Tillotts Pharma AG	Anti-tnf alpha-antibodies and functional fragments thereof
HUE054261T2 (hu) *	2017-09-19	2021-08-30	Tillotts Pharma Ag	Antitest variánsok
EP3456737B1 (en) *	2017-09-19	2024-02-14	Tillotts Pharma Ag	Antibody variants
ES2991804T3 (es) *	2017-09-19	2024-12-04	Tillotts Pharma Ag	Variantes de anticuerpos
WO2020114616A1 (en)	2018-12-07	2020-06-11	Tillotts Pharma Ag	Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
EP1690934A3 (en)	1990-01-12	2008-07-30	Abgenix, Inc.	Generation of xenogeneic antibodies
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de)	1990-08-29	2005-08-15	Genpharm Int	Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9109645D0 (en)	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
US5919452A (en)	1991-03-18	1999-07-06	New York University	Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
IE922437A1 (en)	1991-07-25	1993-01-27	Idec Pharma Corp	Recombinant antibodies for human therapy
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es)	1991-12-02	2010-06-24	Medimmune Limited	Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
NO309690B1 (no)	1995-01-23	2001-03-12	Western Atlas Int Inc	Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
CA2219361C (en)	1995-04-27	2012-02-28	Abgenix, Inc.	Human antibodies derived from immunized xenomice
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DK0929578T3 (da) *	1996-02-09	2003-08-25	Abbott Lab Bermuda Ltd	Humane antistoffer, der binder human TNFalfa
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
EP1500329B1 (en)	1996-12-03	2012-03-21	Amgen Fremont Inc.	Human antibodies that specifically bind human TNF alpha
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
BRPI9809391B8 (pt)	1997-04-14	2021-05-25	Amgen Res Munich Gmbh	processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
AU1728800A (en)	1998-11-18	2000-06-05	Genentech Inc.	Antibody variants with higher binding affinity compared to parent antibodies
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
US7431927B2 (en)	2005-03-24	2008-10-07	Epitomics, Inc.	TNFα-neutralizing antibodies
NZ563580A (en)	2005-06-07	2010-09-30	Esbatech An Alcon Biomedical R	Stable and soluble antibodies inhibiting TNFaplha
MX345039B (es)	2008-06-25	2017-01-16	Esbatech Alcon Biomed Res Unit	Anticuerpos estables y solubles que inhiben el tnfa.
CN104004094B (zh)	2008-06-25	2017-09-22	艾斯巴技术-诺华有限责任公司	使用通用抗体构架进行的兔抗体的人源化
MX2011000009A (es)	2008-07-10	2011-08-15	Esbatech Alcon Biomed Res Unit	Metodos y composiciones para la administracion mejorada de macromoleculas.
WO2011127141A1 (en) *	2010-04-07	2011-10-13	Abbott Laboratories	TNF-α BINDING PROTEINS
CN108314733A (zh) *	2010-07-16	2018-07-24	埃博灵克斯股份有限公司	修饰的单结构域抗原结合分子及其应用
JP5767708B2 (ja)	2010-09-30	2015-08-19	ツェンドゥーカンホンバイオテクノロジーズカンパニーリミテッド	ヒト化抗ヒト腫瘍壊死因子α（ＴＮＦ−α）抗体およびその抗原結合性フラグメント（Ｆａｂ）およびその使用方法
EP3013864A1 (en)	2013-06-26	2016-05-04	Numab AG	Novel antibody frameworks
US9416197B2 (en) *	2013-11-01	2016-08-16	Ibc Pharmaceuticals, Inc.	Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
MX373485B (es) *	2014-03-26	2020-04-27	Cell Medica Switzerland Ag	Miembros de unión al factor de necrosis tumoral (tnf) alfa.
WO2017158084A1 (en)	2016-03-17	2017-09-21	Numab Innovation Ag	ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
EP3219727B1 (en)	2016-03-17	2020-12-16	Tillotts Pharma AG	Anti-tnf alpha-antibodies and functional fragments thereof
CN108884156B (zh)	2016-03-17	2021-10-01	努玛创新有限公司	抗TNFα抗体及其功能片段
SMT202000706T1 (it) *	2016-03-17	2021-01-05	Tillotts Pharma Ag	Anticorpi anti-tnf alfa e frammenti funzionali di essi
HUE054261T2 (hu) *	2017-09-19	2021-08-30	Tillotts Pharma Ag	Antitest variánsok

2016
- 2016-03-17 SM SM20200706T patent/SMT202000706T1/it unknown
- 2016-03-17 SI SI201631040T patent/SI3219726T1/sl unknown
- 2016-03-17 PT PT161609078T patent/PT3219726T/pt unknown
- 2016-03-17 ES ES16160907T patent/ES2836349T3/es active Active
- 2016-03-17 PL PL16160907T patent/PL3219726T3/pl unknown
- 2016-03-17 DK DK16160907.8T patent/DK3219726T3/da active
- 2016-03-17 RS RS20210112A patent/RS61374B1/sr unknown
- 2016-03-17 LT LTEP16160907.8T patent/LT3219726T/lt unknown
- 2016-03-17 HU HUE16160907A patent/HUE052773T2/hu unknown
- 2016-03-17 EP EP16160907.8A patent/EP3219726B1/en active Active
2017
- 2017-03-16 PL PL17710748.9T patent/PL3430043T3/pl unknown
- 2017-03-16 RS RS20231087A patent/RS64830B1/sr unknown
- 2017-03-16 EA EA201891788A patent/EA039760B1/ru unknown
- 2017-03-16 KR KR1020227040533A patent/KR20220158877A/ko not_active Ceased
- 2017-03-16 UA UAA201809317A patent/UA128715C2/uk unknown
- 2017-03-16 IL IL261031A patent/IL261031B2/en unknown
- 2017-03-16 DK DK17710748.9T patent/DK3430043T5/da active
- 2017-03-16 TN TNP/2018/000298A patent/TN2018000298A1/en unknown
- 2017-03-16 PT PT177107489T patent/PT3430043T/pt unknown
- 2017-03-16 GE GEAP201714876A patent/GEP20217307B/en unknown
- 2017-03-16 ES ES17710748T patent/ES2963221T3/es active Active
- 2017-03-16 SG SG11201807062RA patent/SG11201807062RA/en unknown
- 2017-03-16 CR CR20180448A patent/CR20180448A/es unknown
- 2017-03-16 KR KR1020187022632A patent/KR102470235B1/ko active Active
- 2017-03-16 ES ES23192170T patent/ES3043897T3/es active Active
- 2017-03-16 MY MYPI2018001566A patent/MY194041A/en unknown
- 2017-03-16 AU AU2017235387A patent/AU2017235387B2/en active Active
- 2017-03-16 EP EP23192170.1A patent/EP4275745B1/en active Active
- 2017-03-16 MX MX2018011258A patent/MX2018011258A/es unknown
- 2017-03-16 US US16/085,506 patent/US11459383B2/en active Active
- 2017-03-16 JO JOP/2017/0064A patent/JOP20170064B1/ar active
- 2017-03-16 CA CA3011784A patent/CA3011784C/en active Active
- 2017-03-16 FI FIEP17710748.9T patent/FI3430043T3/fi active
- 2017-03-16 HU HUE17710748A patent/HUE064238T2/hu unknown
- 2017-03-16 GE GEAP202114876A patent/GEAP202114876A/en unknown
- 2017-03-16 MA MA43717A patent/MA43717B1/fr unknown
- 2017-03-16 SI SI201731446T patent/SI3430043T1/sl unknown
- 2017-03-16 MD MDE20190099T patent/MD3430043T2/ro unknown
- 2017-03-16 JP JP2019500013A patent/JP7129398B2/ja active Active
- 2017-03-16 EP EP17710748.9A patent/EP3430043B1/en active Active
- 2017-03-16 IL IL322669A patent/IL322669A/en unknown
- 2017-03-16 WO PCT/EP2017/056237 patent/WO2017158092A1/en not_active Ceased
- 2017-03-16 LT LTEPPCT/EP2017/056237T patent/LT3430043T/lt unknown
- 2017-03-16 HR HRP20231464TT patent/HRP20231464T1/hr unknown
- 2017-03-16 CN CN201780015298.5A patent/CN109071650B/zh active Active
- 2017-03-16 SM SM20230429T patent/SMT202300429T1/it unknown
- 2017-03-17 AR ARP170100675A patent/AR107917A1/es unknown
- 2017-03-17 UY UY0001037157A patent/UY37157A/es not_active Application Discontinuation
- 2017-03-17 TW TW111145252A patent/TWI829444B/zh active
- 2017-03-17 TW TW106108832A patent/TWI784945B/zh active
2018
- 2018-09-04 ZA ZA2018/05919A patent/ZA201805919B/en unknown
- 2018-09-06 PH PH12018501907A patent/PH12018501907A1/en unknown
- 2018-09-14 CL CL2018002649A patent/CL2018002649A1/es unknown
- 2018-09-16 SA SA518400027A patent/SA518400027B1/ar unknown
- 2018-09-17 CO CONC2018/0009783A patent/CO2018009783A2/es unknown
2021
- 2021-01-13 CY CY20211100021T patent/CY1123784T1/el unknown
- 2021-01-22 HR HRP20210123TT patent/HRP20210123T1/hr unknown
- 2021-04-22 JO JOJO/P/2021/0085A patent/JOP20210085B1/ar active
- 2021-11-04 ZA ZA2021/08600A patent/ZA202108600B/en unknown
- 2021-11-04 ZA ZA2021/08599A patent/ZA202108599B/en unknown
- 2021-11-04 ZA ZA2021/08602A patent/ZA202108602B/en unknown
- 2021-11-04 ZA ZA2021/08601A patent/ZA202108601B/en unknown
2022
- 2022-06-06 JP JP2022091271A patent/JP2022130407A/ja active Pending
- 2022-08-18 US US17/890,857 patent/US12043663B2/en active Active
- 2022-10-03 US US17/958,759 patent/US12209122B2/en active Active
2024
- 2024-09-18 AU AU2024219840A patent/AU2024219840A1/en active Pending

Also Published As

Publication number	Publication date
HUE064238T2 (hu)	2024-02-28
JP2022130407A (ja)	2022-09-06
EP4275745A3 (en)	2023-12-20
CL2018002649A1 (es)	2018-11-09
DK3219726T3 (da)	2020-12-07
CO2018009783A2 (es)	2018-09-28
FI3430043T3 (fi)	2023-11-17
ZA201805919B (en)	2024-12-18
PL3219726T3 (pl)	2021-07-19
ES3043897T3 (en)	2025-11-26
MY194041A (en)	2022-11-09
SMT202000706T1 (it)	2021-01-05
US11459383B2 (en)	2022-10-04
AR107917A1 (es)	2018-06-28
EP3430043A1 (en)	2019-01-23
ZA202108602B (en)	2022-03-30
GEAP202114876A (en)	2021-05-13
HRP20231464T1 (hr)	2024-03-01
EP3219726A1 (en)	2017-09-20
WO2017158092A1 (en)	2017-09-21
TWI829444B (zh)	2024-01-11
CA3011784C (en)	2024-04-23
JP2019512268A (ja)	2019-05-16
EP4275745B1 (en)	2025-07-16
CN109071650A (zh)	2018-12-21
ZA202108601B (en)	2022-03-30
TN2018000298A1 (en)	2020-01-16
PH12018501907A1 (en)	2019-06-17
NZ745999A (en)	2024-08-30
EP4275745A2 (en)	2023-11-15
MD3430043T2 (ro)	2024-02-29
US20210198353A1 (en)	2021-07-01
EA201891788A1 (ru)	2019-01-31
ZA202108600B (en)	2022-03-30
HRP20210123T1 (hr)	2021-03-05
KR20180120149A (ko)	2018-11-05
JP7129398B2 (ja)	2022-09-01
CA3011784A1 (en)	2017-09-21
EP3219726B1 (en)	2020-12-02
RS64830B1 (sr)	2023-12-29
IL261031A (en)	2018-10-31
SA518400027B1 (ar)	2022-03-06
CR20180448A (es)	2019-01-25
BR112018016667A2 (pt)	2019-02-05
PT3430043T (pt)	2023-11-23
ES2963221T3 (es)	2024-03-26
JOP20170064B1 (ar)	2021-08-17
EA039760B1 (ru)	2022-03-10
TW201739766A (zh)	2017-11-16
JOP20210085B1 (ar)	2025-10-01
TWI784945B (zh)	2022-12-01
HUE052773T2 (hu)	2021-05-28
MX2018011258A (es)	2019-02-13
MA43717B1 (fr)	2023-11-30
US12209122B2 (en)	2025-01-28
IL261031B2 (en)	2026-01-01
RS61374B1 (sr)	2021-02-26
AU2024219840A1 (en)	2024-10-10
AU2017235387A1 (en)	2018-09-27
SG11201807062RA (en)	2018-09-27
PT3219726T (pt)	2020-12-15
GEP20217307B (en)	2021-10-25
CN109071650B (zh)	2022-05-13
TW202311288A (zh)	2023-03-16
AU2017235387B2 (en)	2024-06-27
IL261031B1 (en)	2025-09-01
PL3430043T3 (pl)	2024-03-11
JOP20210085A1 (ar)	2023-01-30
CY1123784T1 (el)	2022-05-27
IL322669A (en)	2025-10-01
UA128715C2 (uk)	2024-10-09
LT3430043T (lt)	2023-12-27
US20230272059A1 (en)	2023-08-31
UY37157A (es)	2017-10-31
ZA202108599B (en)	2022-03-30
US20230279091A1 (en)	2023-09-07
MA43717A (fr)	2018-11-28
DK3430043T5 (da)	2024-09-23
EP3430043B1 (en)	2023-08-30
US12043663B2 (en)	2024-07-23
SMT202300429T1 (it)	2024-01-10
SI3219726T1 (sl)	2021-02-26
SI3430043T1 (sl)	2024-01-31
KR20220158877A (ko)	2022-12-01
DK3430043T3 (da)	2023-11-27
KR102470235B1 (ko)	2022-11-24
ES2836349T3 (es)	2021-06-24

Publication	Publication Date	Title
IL272183A (en)	2020-03-31	Anti-cd8 antibodies and uses thereof
LT3280441T (lt)	2021-11-25	Anti-sortilino antikūnai ir jų naudojimo būdai
LT3250610T (lt)	2023-09-25	Fcrn antikūnai ir jų panaudojimo būdai
LT3491025T (lt)	2023-11-27	Fcrn antikūnai ir jų panaudojimo būdai
IL262092A (en)	2018-11-29	Humanized anti-pacap antibodies and uses thereof
LT3515490T (lt)	2022-11-10	Antikūnai prieš signalą reguliuojantį baltymą alfa, ir naudojimo būdai
LT3353212T (lt)	2021-12-27	Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
LT3274370T (lt)	2020-02-10	Antikūnai prieš ceacam6 ir jų panaudojimas
LT3443009T (lt)	2021-12-27	Anti-tim-3 antikūnai ir kompozicijos
DK3468990T3 (da)	2024-06-24	Anti-C5-antistoffer og anvendelser deraf
LT3347379T (lt)	2020-05-11	Anti-tigit antikūnai, anti-pvrig antikūnai ir jų kombinacijos
LT3215532T (lt)	2020-01-10	Anti-tim3 antikūnai ir jų naudojimo būdai
LT3303394T (lt)	2020-10-12	Anti-ctla-4 antikūnai ir jų naudojimo būdai
LT3333191T (lt)	2020-12-10	Anti-c10orf54 antikūnai ir jų panaudojimas
LT3532499T (lt)	2021-08-10	Antikūnai prieš il-33 ir jų panaudojimas
LT3558390T (lt)	2024-11-11	Amanitino ir antikūnų konjugatai
LT3227311T (lt)	2022-02-25	Įterpiami variabilūs antikūnų fragmentai ir nkg2d ligandų modifikuoti a1-a2 domenai
EP3592386A4 (en)	2021-01-13	ANTI-C5 ANTIBODIES AND THEIR USES
LT3295951T (lt)	2020-09-25	Anti-pvrig antikūnai ir naudojimo būdai
LT3430043T (lt)	2023-12-27	Anti-tnf alfa antikūnai ir funkciniai jų fragmentai
LT3148579T (lt)	2021-05-25	Anti-gitr antikūnai ir jų panaudojimo būdai
LT3126388T (lt)	2019-08-26	Antikūnai prieš egfrviii ir jų panaudojimo būdai
LT3525583T (lt)	2025-11-10	Anti-c1s antikūnai ir jų naudojimo būdai
IL262776A (en)	2018-12-31	Humanized anti-il-1r3 antibodies
PL3219727T3 (pl)	2021-05-17	Przeciwciała anty-TNF alfa i ich funkcjonalne fragmenty